Journal
SCHIZOPHRENIA BULLETIN
Volume 38, Issue 5, Pages 936-941Publisher
OXFORD UNIV PRESS
DOI: 10.1093/schbul/sbs012
Keywords
NMDA; negative symptoms; memory consolidation; cognitive behavioral; therapy; D-cycloserine
Categories
Funding
- National Institute of Mental Health (NIMH) [K24 MH002025]
Ask authors/readers for more resources
As a partial agonist at the glycine site of the NMDA receptor, D-cycloserine (DCS) has been viewed as lacking potency to fully test the NMDA receptor hypofunction theory of schizophrenia. However, findings of full agonist activity at a subset of NMDA receptors that may have particular relevance to schizophrenia, plus a growing body of evidence demonstrating enhancement of learning and neuroplasticity in animal models, suggest novel therapeutic strategies with DCS in schizophrenia. Preliminary studies with once-weekly administration have supported this potential new role for DCS in schizophrenia by demonstrating benefit for negative symptoms, memory consolidation, and facilitation of cognitive behavioral therapy for delusions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available